Committee MemberEmploymentConsultantSpeakers BureauOwnership/Partnership/PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert Witness
Clyde W. Yancy (Chair)Northwestern University, Feinberg School of Medicine—Vice Dean, Diversity & Inclusion; Magerstadt Professor of Medicine; Chief, Division of CardiologyNoneNoneNoneNoneNoneNone
James L. Januzzi Jr. (Vice Chair)Massachusetts General Hospital—Professor of Medicine, Harvard Medical School
  • Critical Diagnostics

  • Novartis

  • Philips

  • Roche Diagnostics

NoneNone
  • Amgen (DSMB)

  • Boehringer Ingelheim (CEC)

  • Janssen Pharmaceuticals (CEC)

  • Singulex

  • Roche Diagnostics

  • Cleveland Heart Labs

NoneNone
Larry A. AllenUniversity of Colorado School of Medicine—Associate Professor of Medicine
  • Amgen

  • Janssen Scientific Affairs

  • Novartis

  • St. Jude

  • ZS Pharma

NoneNoneNone
  • Circulation Heart Failure

None
Javed ButlerStony Brook University School of Medicine—Professor of Medicine
  • Bayer

  • Boehringer Ingelheim

  • CardioCell

  • CVRx

  • Gilead

  • Janssen

  • Medtronic

  • Merck

  • Novartis

  • Relypsa

  • ZS Pharma

  • Novartis

None
  • Amgen (DSMB)

  • Bristol-Myers Squibb (DSMB)

  • JACC

  • JACC Heart Failure

  • Circulation

None
Leslie L. DavisUniversity of North Carolina, Greensboro—Associate Professor of NursingNoneNoneNoneNoneNoneNone
Gregg C. FonarowDavid Geffen School of Medicine, UCLA Division of Cardiology—Professor of Medicine
  • Amgen

  • Janssen

  • Medtronic

  • Novartis

  • St. Jude

  • ZS Pharma

NoneNone
  • Medtronic

  • Novartis

NoneNone
Nasrien E. IbrahimMassachusetts General Hospital—Clinical Research Fellow
  • Novartis

NoneNoneNoneNoneNone
Mariell JessupFondation Leducq—Chief Scientific OfficerNoneNoneNoneNoneNoneNone
JoAnn LindenfeldVanderbilt University—Director, Heart Failure and Transplantation Program
  • Abbott

  • Boston Scientific

  • Cardiomems

  • CVRx

  • Janssen

  • Novartis

  • Relypsa

  • RESMED

NoneNone
  • AstraZeneca

  • Novartis

  • AstraZeneca

  • St. Jude

None
Thomas M. MaddoxBJC Healthcare/WashingtonUniversity School of Medicine--Director, Health Systems Innovation Lab; Professor of Medicine (Cardiology)NoneNoneNoneNoneNoneNone
Frederick A. MasoudiUniversity of Colorado Anschutz Medical Campus—Professor of MedicineNoneNoneNoneNoneNoneNone
Shweta R. MotiwalaBeth Israel Deaconess Medical Center—Instructor of Medicine, Harvard Medical SchoolNoneNoneNoneNoneNoneNone
J. Herbert PattersonUNC Eshelman School of Pharmacy—Professor of Pharmacy and Research; Professor of Medicine
  • Novartis

NoneNone
  • Amgen

  • Novartis

  • Otsuka America

NoneNone
Mary Norine WalshSt. Vincent Heart Center—Medical Director, Heart Failure and Cardiac TransplantationNoneNoneNoneNoneNoneNone
Alan WassermanThe George Washington University School of Medicine and Health Sciences—Eugene Meyer Professor of Medicine; Chairman, Department of MedicineNoneNoneNoneNoneNoneNone

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

CEC = Clinical Events Committee; DSMB = Data Safety Monitoring Board; JACC = Journal of the American College of Cardiology.

  • Significant relationship.

  • No financial benefit.